SELLAS Life Sciences Delivers Oral Presentation Of SLS009 Phase 1 Data For Acute Myeloid Leukemia Patients At 2024 European School of Haematology Conference
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences announced successful Phase 1 results for SLS009 in treating acute myeloid leukemia (AML) at the 2024 European School of Haematology Conference. The study met all objectives, including pharmacokinetic, pharmacodynamic, safety, and clinical activity. A notable achievement was a complete remission (CR) in a patient after three months, lasting eight months, with one-year survival at the latest assessment. This marks the first instance of CR with CDK9 inhibition monotherapy in a relapsed/refractory AML patient. Phase 2a data is expected in March and Q2 2024.
March 01, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SELLAS Life Sciences announced promising Phase 1 results for SLS009 in AML treatment, achieving significant milestones including the first-ever CR with CDK9 inhibition. Phase 2a data is anticipated in March and Q2 2024.
The positive outcome of the Phase 1 trial for SLS009, especially achieving complete remission in a relapsed/refractory AML patient through CDK9 inhibition monotherapy, is a significant milestone for SELLAS Life Sciences. This achievement not only demonstrates the potential efficacy of SLS009 but also positions the company as a leader in AML treatment innovation. The anticipation of Phase 2a data in the near future could further bolster investor confidence and potentially lead to a positive short-term impact on SELLAS Life Sciences' stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100